Annual CFO
$6.66 M
+$21.86 M+143.85%
December 31, 2024
Summary
- As of March 12, 2025, TXG annual cash flow from operations is $6.66 million, with the most recent change of +$21.86 million (+143.85%) on December 31, 2024.
- During the last 3 years, TXG annual CFO has risen by +$28.04 million (+131.18%).
- TXG annual CFO is now -80.75% below its all-time high of $34.63 million, reached on December 31, 2019.
Performance
TXG Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$6.75 M
-$28.39 M-131.18%
December 31, 2024
Summary
- As of March 12, 2025, TXG quarterly cash flow from operations is -$6.75 million, with the most recent change of -$28.39 million (-131.18%) on December 31, 2024.
- Over the past year, TXG quarterly CFO has dropped by -$28.39 million (-131.18%).
- TXG quarterly CFO is now -126.20% below its all-time high of $25.76 million, reached on December 31, 2023.
Performance
TXG Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
$6.66 M
-$32.51 M-82.99%
December 31, 2024
Summary
- As of March 12, 2025, TXG TTM cash flow from operations is $6.66 million, with the most recent change of -$32.51 million (-82.99%) on December 31, 2024.
- Over the past year, TXG TTM CFO has dropped by -$32.51 million (-82.99%).
- TXG TTM CFO is now -82.99% below its all-time high of $39.17 million, reached on September 30, 2024.
Performance
TXG TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
TXG Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +143.8% | -131.2% | -83.0% |
| 3 y3 years | +131.2% | -131.2% | -83.0% |
| 5 y5 years | -80.8% | -131.2% | -83.0% |
TXG Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +119.8% | -126.2% | +73.3% | -83.0% | +111.5% |
| 5 y | 5-year | -80.8% | +103.1% | -126.2% | +94.8% | -83.0% | +103.0% |
| alltime | all time | -80.8% | +103.1% | -126.2% | +94.8% | -83.0% | +103.0% |
10x Genomics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $6.66 M(-143.9%) | -$6.75 M(-131.2%) | $6.66 M(-83.0%) |
| Sep 2024 | - | $21.64 M(+188.7%) | $39.17 M(-603.8%) |
| Jun 2024 | - | $7.50 M(-147.7%) | -$7.78 M(-71.0%) |
| Mar 2024 | - | -$15.72 M(-161.0%) | -$26.80 M(+76.3%) |
| Dec 2023 | -$15.20 M(-54.8%) | $25.76 M(-201.8%) | -$15.20 M(-44.2%) |
| Sep 2023 | - | -$25.30 M(+119.5%) | -$27.23 M(+137.0%) |
| Jun 2023 | - | -$11.53 M(+179.4%) | -$11.49 M(-32.1%) |
| Mar 2023 | - | -$4.13 M(-130.1%) | -$16.93 M(-49.6%) |
| Dec 2022 | -$33.61 M(+57.2%) | $13.72 M(-243.5%) | -$33.61 M(-19.1%) |
| Sep 2022 | - | -$9.56 M(-43.6%) | -$41.52 M(-28.6%) |
| Jun 2022 | - | -$16.96 M(-18.5%) | -$58.18 M(+52.7%) |
| Mar 2022 | - | -$20.80 M(-458.3%) | -$38.09 M(+78.2%) |
| Dec 2021 | -$21.37 M | $5.80 M(-122.1%) | -$21.37 M(-86.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$26.22 M(-940.3%) | -$157.35 M(-15.7%) |
| Jun 2021 | - | $3.12 M(-176.4%) | -$186.77 M(-14.9%) |
| Mar 2021 | - | -$4.08 M(-96.9%) | -$219.40 M(+0.7%) |
| Dec 2020 | -$217.90 M(-729.3%) | -$130.18 M(+134.0%) | -$217.90 M(+168.9%) |
| Sep 2020 | - | -$55.63 M(+88.5%) | -$81.02 M(+645.5%) |
| Jun 2020 | - | -$29.52 M(+1045.9%) | -$10.87 M(-147.8%) |
| Mar 2020 | - | -$2.58 M(-138.4%) | $22.73 M(-34.3%) |
| Dec 2019 | $34.63 M(-145.3%) | $6.70 M(-53.9%) | $34.63 M(+24.0%) |
| Sep 2019 | - | $14.53 M(+255.8%) | $27.93 M(+108.4%) |
| Jun 2019 | - | $4.08 M(-56.2%) | $13.40 M(+43.8%) |
| Mar 2019 | - | $9.32 M | $9.32 M |
| Dec 2018 | -$76.41 M(+614.2%) | - | - |
| Dec 2017 | -$10.70 M | - | - |
FAQ
- What is 10x Genomics annual cash flow from operations?
- What is the all time high annual CFO for 10x Genomics?
- What is 10x Genomics annual CFO year-on-year change?
- What is 10x Genomics quarterly cash flow from operations?
- What is the all time high quarterly CFO for 10x Genomics?
- What is 10x Genomics quarterly CFO year-on-year change?
- What is 10x Genomics TTM cash flow from operations?
- What is the all time high TTM CFO for 10x Genomics?
- What is 10x Genomics TTM CFO year-on-year change?
What is 10x Genomics annual cash flow from operations?
The current annual CFO of TXG is $6.66 M
What is the all time high annual CFO for 10x Genomics?
10x Genomics all-time high annual cash flow from operations is $34.63 M
What is 10x Genomics annual CFO year-on-year change?
Over the past year, TXG annual cash flow from operations has changed by +$21.86 M (+143.85%)
What is 10x Genomics quarterly cash flow from operations?
The current quarterly CFO of TXG is -$6.75 M
What is the all time high quarterly CFO for 10x Genomics?
10x Genomics all-time high quarterly cash flow from operations is $25.76 M
What is 10x Genomics quarterly CFO year-on-year change?
Over the past year, TXG quarterly cash flow from operations has changed by -$28.39 M (-131.18%)
What is 10x Genomics TTM cash flow from operations?
The current TTM CFO of TXG is $6.66 M
What is the all time high TTM CFO for 10x Genomics?
10x Genomics all-time high TTM cash flow from operations is $39.17 M
What is 10x Genomics TTM CFO year-on-year change?
Over the past year, TXG TTM cash flow from operations has changed by -$32.51 M (-82.99%)